Almost 2 Years Ago
1 Min Read
MRSN up 35%. A closer look at the stock:
Mersana Therapeutics Inc (MRSN) is trading 35% higher at $6.8 today.
- Earnings on Monday night missed estimates by 5.77%
- Revenue rose by $2 million over last year's quarter due to increased sales of XIPERE (triamcinolone acetonide injectable suspension), which is being developed as a treatment for suprachoroidal neovascularization (SCN)
- Global collaboration with GSK that provides the pharmaceutical company an exclusive option to co-develop and commercialize XMT-2056, a cancer-focused therapy
- Mersana is also eligible to receive up to $1.36 billion in the form of an option exercise payment and development, regulatory and commercial milestone payments if GSK exercises its option
- Collaboration expected to initiate a Phase 1 trial of XMT-2056 to investigate its potential in a range of HER2-expressing cancers
Mersana Therapeutics Inc has been trading between a 52-week high of $14.8 and a 52-week low of $2.68. The stock has a market cap of $660 Million.
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana's lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana's second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana's customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study.
Headlines
Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy
Benzinga 08-09-22
Recap: Mersana Therapeutics Q2 Earnings
Benzinga 08-08-22
Mersana Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation (NASDAQ:MRSN)
Seeking Alpha 08-08-22
Mersana Therapeutics GAAP EPS of -$0.55 misses by $0.03, revenue of $4.28M beats by $2.08M
Seeking Alpha 08-08-22
Earnings Scheduled For August 8, 2022
Benzinga 08-08-22
Recommended Articles
